BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Topics » Briefs » In the clinic

In the clinic
In the clinic RSS Feed RSS

In the clinic for April 29, 2025

April 29, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akeso, Alterity, Boehringer, CG Oncology, Chemomab, Immunitybio, J&J, Levicept, Merck, Oncoinvent, Pfizer, Revolution, Senti, Urogen, Yoltech.
Read More

In the clinic for April 29, 2025

April 29, 2025
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akeso, Asceltis, Astrazeneca.
Read More

In the clinic for April 28, 2025

April 28, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbott, Histosonics, J&J, Medtronic.
Read More

In the clinic for April 28, 2025

April 28, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alx Oncology, Cytoagents, Genentech, Geovax, Neurocrine, Realta, Roche, Vyne.
Read More

In the clinic for April 25, 2025

April 25, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cordis.
Read More

In the clinic for April 25, 2025

April 25, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Bioxodes, Inmagene, Insmed, Ipsen, Mineralys, Spyglass.
Read More

In the clinic for April 24, 2025

April 24, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Istar Medical.
Read More

In the clinic for April 24, 2025

April 24, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akeso, Ascletis, Braintree, BMS, Cellenkos, Unity.
Read More

In the clinic for April 23, 2025

April 23, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cleveland Diagnostics, Viz.ai.
Read More

In the clinic for April 23, 2025

April 23, 2025
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Cellphire, Ferring, Lipella, Metavia, Novadip.
Read More
Previous 1 2 … 45 46 47 48 49 50 51 52 53 … 326 327 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing